Fig. 2: Potential uses of molecular response in the prospective trials.
From: Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
This figure shows two examples of how molecular response (MR)Â can be incorporated into prospective clinical trials. In the Patient Stratification example, MR is applied to identify a patient population likely experiencing less or little benefit from one treatment regimen earlier than scans and randomize those patients to continue that treatment regimen vs adding or switching therapies. The Clinical Trial Enrichment example, patients with increasing ctDNA early on treatment with standard of care (SOC) are considered eligible for a clinical trial.
